Search

Your search keyword '"Doppler, Valérie"' showing total 23 results
Start Over Author "Doppler, Valérie"
23 results on '"Doppler, Valérie"'

1. Supplementary Table 1 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors

Author

Teixeira, Luis, primary, Medioni, Jacques, primary, Garibal, Julie, primary, Adotevi, Olivier, primary, Doucet, Ludovic, primary, Durey, Marie-Agnès Dragon, primary, Ghrieb, Zineb, primary, Kiladjian, Jean-Jacques, primary, Brizard, Mara, primary, Laheurte, Caroline, primary, Wehbe, Maria, primary, Pliquet, Elodie, primary, Escande, Marie, primary, Defrance, Rémy, primary, Culine, Stephane, primary, Oudard, Stephane, primary, Wain-Hobson, Simon, primary, Doppler, Valérie, primary, Huet, Thierry, primary, and Langlade-Demoyen, Pierre, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Figure 2 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors

Author

Teixeira, Luis, primary, Medioni, Jacques, primary, Garibal, Julie, primary, Adotevi, Olivier, primary, Doucet, Ludovic, primary, Durey, Marie-Agnès Dragon, primary, Ghrieb, Zineb, primary, Kiladjian, Jean-Jacques, primary, Brizard, Mara, primary, Laheurte, Caroline, primary, Wehbe, Maria, primary, Pliquet, Elodie, primary, Escande, Marie, primary, Defrance, Rémy, primary, Culine, Stephane, primary, Oudard, Stephane, primary, Wain-Hobson, Simon, primary, Doppler, Valérie, primary, Huet, Thierry, primary, and Langlade-Demoyen, Pierre, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure 1 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors

Author

Teixeira, Luis, primary, Medioni, Jacques, primary, Garibal, Julie, primary, Adotevi, Olivier, primary, Doucet, Ludovic, primary, Durey, Marie-Agnès Dragon, primary, Ghrieb, Zineb, primary, Kiladjian, Jean-Jacques, primary, Brizard, Mara, primary, Laheurte, Caroline, primary, Wehbe, Maria, primary, Pliquet, Elodie, primary, Escande, Marie, primary, Defrance, Rémy, primary, Culine, Stephane, primary, Oudard, Stephane, primary, Wain-Hobson, Simon, primary, Doppler, Valérie, primary, Huet, Thierry, primary, and Langlade-Demoyen, Pierre, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Table 5 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors

Author

Teixeira, Luis, primary, Medioni, Jacques, primary, Garibal, Julie, primary, Adotevi, Olivier, primary, Doucet, Ludovic, primary, Durey, Marie-Agnès Dragon, primary, Ghrieb, Zineb, primary, Kiladjian, Jean-Jacques, primary, Brizard, Mara, primary, Laheurte, Caroline, primary, Wehbe, Maria, primary, Pliquet, Elodie, primary, Escande, Marie, primary, Defrance, Rémy, primary, Culine, Stephane, primary, Oudard, Stephane, primary, Wain-Hobson, Simon, primary, Doppler, Valérie, primary, Huet, Thierry, primary, and Langlade-Demoyen, Pierre, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Table 4 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors

Author

Teixeira, Luis, primary, Medioni, Jacques, primary, Garibal, Julie, primary, Adotevi, Olivier, primary, Doucet, Ludovic, primary, Durey, Marie-Agnès Dragon, primary, Ghrieb, Zineb, primary, Kiladjian, Jean-Jacques, primary, Brizard, Mara, primary, Laheurte, Caroline, primary, Wehbe, Maria, primary, Pliquet, Elodie, primary, Escande, Marie, primary, Defrance, Rémy, primary, Culine, Stephane, primary, Oudard, Stephane, primary, Wain-Hobson, Simon, primary, Doppler, Valérie, primary, Huet, Thierry, primary, and Langlade-Demoyen, Pierre, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Table 2 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors

Author

Teixeira, Luis, primary, Medioni, Jacques, primary, Garibal, Julie, primary, Adotevi, Olivier, primary, Doucet, Ludovic, primary, Durey, Marie-Agnès Dragon, primary, Ghrieb, Zineb, primary, Kiladjian, Jean-Jacques, primary, Brizard, Mara, primary, Laheurte, Caroline, primary, Wehbe, Maria, primary, Pliquet, Elodie, primary, Escande, Marie, primary, Defrance, Rémy, primary, Culine, Stephane, primary, Oudard, Stephane, primary, Wain-Hobson, Simon, primary, Doppler, Valérie, primary, Huet, Thierry, primary, and Langlade-Demoyen, Pierre, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 3 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors

Author

Teixeira, Luis, primary, Medioni, Jacques, primary, Garibal, Julie, primary, Adotevi, Olivier, primary, Doucet, Ludovic, primary, Durey, Marie-Agnès Dragon, primary, Ghrieb, Zineb, primary, Kiladjian, Jean-Jacques, primary, Brizard, Mara, primary, Laheurte, Caroline, primary, Wehbe, Maria, primary, Pliquet, Elodie, primary, Escande, Marie, primary, Defrance, Rémy, primary, Culine, Stephane, primary, Oudard, Stephane, primary, Wain-Hobson, Simon, primary, Doppler, Valérie, primary, Huet, Thierry, primary, and Langlade-Demoyen, Pierre, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table 3 from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors

Author

Teixeira, Luis, primary, Medioni, Jacques, primary, Garibal, Julie, primary, Adotevi, Olivier, primary, Doucet, Ludovic, primary, Durey, Marie-Agnès Dragon, primary, Ghrieb, Zineb, primary, Kiladjian, Jean-Jacques, primary, Brizard, Mara, primary, Laheurte, Caroline, primary, Wehbe, Maria, primary, Pliquet, Elodie, primary, Escande, Marie, primary, Defrance, Rémy, primary, Culine, Stephane, primary, Oudard, Stephane, primary, Wain-Hobson, Simon, primary, Doppler, Valérie, primary, Huet, Thierry, primary, and Langlade-Demoyen, Pierre, primary

Published
2023
Full Text
View/download PDF

9. Data not shown from A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors

Author

Teixeira, Luis, primary, Medioni, Jacques, primary, Garibal, Julie, primary, Adotevi, Olivier, primary, Doucet, Ludovic, primary, Durey, Marie-Agnès Dragon, primary, Ghrieb, Zineb, primary, Kiladjian, Jean-Jacques, primary, Brizard, Mara, primary, Laheurte, Caroline, primary, Wehbe, Maria, primary, Pliquet, Elodie, primary, Escande, Marie, primary, Defrance, Rémy, primary, Culine, Stephane, primary, Oudard, Stephane, primary, Wain-Hobson, Simon, primary, Doppler, Valérie, primary, Huet, Thierry, primary, and Langlade-Demoyen, Pierre, primary

Published
2023
Full Text
View/download PDF

11. Abstract CT021: INVAC-1, an optimized telomerase DNA vaccine in patients with advanced solid tumors: Final results of first-in-human phase I study

Author

Garibal, Julie, primary, Medioni, Jacques, additional, Teixeira, Luis, additional, Adotevi, Olivier, additional, Dragon-Durey, Marie-Agnès, additional, Laheurte, Caroline, additional, Germain, Claire, additional, Escande, Marie, additional, Wehbe, Maria, additional, Doppler, Valérie, additional, Huet, Thierry, additional, and Demoyen, Pierre Langlade, additional

Published
2021
Full Text
View/download PDF

13. A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors

Author

Teixeira, Luis, primary, Medioni, Jacques, additional, Garibal, Julie, additional, Adotevi, Olivier, additional, Doucet, Ludovic, additional, Durey, Marie-Agnès Dragon, additional, Ghrieb, Zineb, additional, Kiladjian, Jean-Jacques, additional, Brizard, Mara, additional, Laheurte, Caroline, additional, Wehbe, Maria, additional, Pliquet, Elodie, additional, Escande, Marie, additional, Defrance, Rémy, additional, Culine, Stephane, additional, Oudard, Stephane, additional, Wain-Hobson, Simon, additional, Doppler, Valérie, additional, Huet, Thierry, additional, and Langlade-Demoyen, Pierre, additional

Published
2020
Full Text
View/download PDF

15. Final results of a phase I study evaluating INVAC-1, a novel DNA vaccine expressing an inactive form of human telomerase reverse transcriptase (hTERT) in patients with advanced solid tumors.

Author

Teixeira, Luis, primary, Medioni, Jacques, additional, Doucet, Ludovic, additional, Angelergues, Antoine, additional, Culine, Stephane, additional, Oudard, Stephane, additional, Brizard, Mara, additional, Ghrieb, Zineb, additional, Adotevi, Olivier, additional, Laheurte, Caroline, additional, Dragon Durey, Marie-Agnès, additional, Laurent-Puig, Pierre, additional, Kiladjian, Jean-Jacques, additional, wain-Hobson, Simon, additional, Doppler, Valérie, additional, DeFrance, Rémy, additional, Garibal, Julie, additional, Huet, Thierry, additional, and Langlade Demoyen, Pierre, additional

Published
2019
Full Text
View/download PDF

16. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

Author

Rosenzwajg, Michelle, primary, Lorenzon, Roberta, additional, Cacoub, Patrice, additional, Pham, Hang Phuong, additional, Pitoiset, Fabien, additional, El Soufi, Karim, additional, RIbet, Claire, additional, Bernard, Claude, additional, Aractingi, Selim, additional, Banneville, Beatrice, additional, Beaugerie, Laurent, additional, Berenbaum, Francis, additional, Champey, Julien, additional, Chazouilleres, Olivier, additional, Corpechot, Christophe, additional, Fautrel, Bruno, additional, Mekinian, Arsène, additional, Regnier, Elodie, additional, Saadoun, David, additional, Salem, Joe-Elie, additional, Sellam, Jérémie, additional, Seksik, Philippe, additional, Daguenel-Nguyen, Anne, additional, Doppler, Valérie, additional, Mariau, Jéremie, additional, Vicaut, Eric, additional, and Klatzmann, David, additional

Published
2018
Full Text
View/download PDF

21. Blood oxidative stress in amyotrophic lateral sclerosis

Author

Bonnefont-Rousselot, Dominique, primary, Lacomblez, Lucette, additional, Jaudon, Marie-Chantal, additional, Lepage, Sylvie, additional, Salachas, François, additional, Bensimon, Gilbert, additional, Bizard, Catherine, additional, Doppler, Valérie, additional, Delattre, Jacques, additional, and Meininger, Vincent, additional

Published
2000
Full Text
View/download PDF

22. SS-3-5 SR-57746A, a growth factor like compound. Dose ranging study of the efficacy using muscle testing and repeated measures of EMG variables in amyotrophic lateral sclerosis (ALS)

Author

Lacomblez, Lucette, primary, Maisonnobe, Thierry, additional, Gouider, Riadh, additional, Doppler, Valérie, additional, Salachas, François, additional, Birouk, Nasa, additional, Douillet, Patrice, additional, Bensimon, Gilbert, additional, Bouche, Pierre, additional, and Meininger, Vincent, additional

Published
1995
Full Text
View/download PDF

23. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.

Author

Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, RIbet C, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Daguenel-Nguyen A, Doppler V, Mariau J, Vicaut E, and Klatzmann D

Subjects
Adult, Autoimmune Diseases immunology, Female, Humans, Immunologic Factors immunology, Interleukin-2 immunology, Male, Middle Aged, Prospective Studies, T-Lymphocytes, Regulatory immunology, Treatment Outcome, Autoimmune Diseases drug therapy, Immunologic Factors administration & dosage, Interleukin-2 administration & dosage, T-Lymphocytes, Regulatory drug effects
Abstract

Objective: Regulatory T cells (Tregs) prevent autoimmunity and control inflammation. Consequently, any autoimmune or inflammatory disease reveals a Treg insufficiency. As low-dose interleukin-2 (ld-IL2) expands and activates Tregs, it has a broad therapeutic potential., Aim: We aimed to assess this potential and select diseases for further clinical development by cross-investigating the effects of ld-IL2 in a single clinical trial treating patients with 1 of 11 autoimmune diseases., Methods: We performed a prospective, open-label, phase I-IIa study in 46 patients with a mild to moderate form of either rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, psoriasis, Behcet's disease, granulomatosis with polyangiitis, Takayasu's disease, Crohn's disease, ulcerative colitis, autoimmune hepatitis and sclerosing cholangitis. They all received ld-IL2 (1 million IU/day) for 5 days, followed by fortnightly injections for 6 months. Patients were evaluated by deep immunomonitoring and clinical evaluation., Results: ld-IL2 was well tolerated whatever the disease and the concomitant treatments. Thorough supervised and unsupervised immunomonitoring demonstrated specific Treg expansion and activation in all patients, without effector T cell activation. Indication of potential clinical efficacy was observed., Conclusion: The dose of IL-2 and treatment scheme used selectively activate and expand Tregs and are safe across different diseases and concomitant treatments. This and preliminary indications of clinical efficacy should licence the launch of phase II efficacy trial of ld-IL2 in various autoimmune and inflammatory diseases., Trial Registration Number: NCT01988506., Competing Interests: Competing interests: MR, RL, PC, FB, BF, PC, JS, DS, CB and DK are inventors for patent applications related to the therapeutic use of ld-IL2, which belongs to their academic institutions and has been licensed to ILTOO Pharma. MR, VD, JM and DK hold shares in ILTOO Pharma. HPP, VD and JM are employees of ILTOO Pharma. No other potential conflicts of interest relevant to this article were reported., (© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results